FEELM
FEELM, the flagship atomization technology platform belonging to SMOORE - the world’s largest vape manufacturer, has won Best Innovation in the Vaping Industry and Sustainable Vaping Award at the UKVIA Industry Forum.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221121005487/en/
FEELM won the UKVIA Best Innovation Award. (Photo: Business Wire)
UKVIA is one of the world's most influential trade associations for the vaping sector. It is also one of the most accredited industrial association in Europe. This is the first time they held an award competition ever since their establishment in 2016. The competition is consisted of three sessions: online application, audiences review, and experts scoring. FEELM Max won the victory after rounds of assessments of more than 300 audiences and 10 experts.
The Best Innovation in the Vaping Industry
The Best Innovation in the Vaping Industry recognized the significant contribution FEELM has made to vaping innovation, particularly its world's first ceramic coil disposable pod solution FEELM Max.
FEELM Max has made a number of breakthrough innovations, including more puffs with the same e-liquid volume versus other coil technologies. Despite heating the same e-liquid volume as other conventional devices, puff numbers increase by more than 25%. FEELM Max achieves a flavour consistency of over 95% as well as a smoother vapour – and there is no dry burning – thanks to Constant Output Control and our Patented Flavour-Lock Technologies. Not only is FEELM Max enhancing the vaping experience, but it is also outperforming other disposables on harm reduction by almost 50%.
To stand still on the path of innovation, FEELM has established China’s first PMTA-standard testing lab besides the now-existing 14 labs globally, to empower our clients facing with the stringent regulations on the industry. This is to prove our determination to drive innovation with technology, and keep providing products with enhanced quality to consumers.
The Sustainable Vaping Award
The Sustainable Vaping Award was given in recognition of FEELM excelling in three key areas: creating sustainable advanced technologies and products; using responsible marketing; and embracing a greener future.
FEELM is credited with building the world's first environmentally friendly disposable electronic atomization device in 2019. In 2022, the world's first ceramic coil disposable pod "FEELM Max" was created and the "FEELM GREEN" series was launched based on it. This series is FEELM Max's main environmental protection solutions, its latest "product is packaging" series has been presented at the major European electronic atomization exhibition, aroused the industry's high attention. In addition, FEELM also created an environmentally friendly zero nicotine e-atomization device this year.
It was also acknowledged that its brand website and social media platforms go to great lengths to restrict those who are under the legal age of vaping to prevent them from accessing any information about electronic atomization products; and that FEELM conducts regular satisfaction surveys on behalf of clients so data can be used to improve customer experience.
FEELM has announced its launching of the Carbon Disclosure Project (CDP), committing to achieve carbon neutrality by 2050, and its automated factory has adopted an energy management system with the purpose of decreasing carbon emissions whilst increasing energy consumption efficiency
The Award is also recognition of FEELM’s cut in carbon emissions of over 500 tons in the last six months, and its aim to lower greenhouse gas emissions and achieve Scope 1 and Scope 2 carbon neutrality by 2050. The company intends to achieve this by improving energy efficiency and increasing the use of renewable energy sources to 30% of total consumption by 2030 and has accordingly introduced a professional carbon neutral energy screening team and internal resources to monitor carbon consumption improvement. It has also partnered with a third-party cleaning company to collect non-hazardous waste for recycling, which in 2020 helped clients reduce single-use plastics by 100 tons – equivalent to 4 million plastic bottles, while in 2021 it reduced its water consumption by 9.4% year-on-year.
Echo liu, FEELM Europe Division Director said:
“We are delighted to have won both awards and honoured by the recognition the UKVIA have given us.”
“A number of leading vaping brands are driven by FEELM Technology, and our vaping devices loaded with FEELM atomizer are now being exported to over 50 countries and regions.”
“FEELM can only realize its corporate vision – “atomization makes life better” – by being sustainable and creating value for society. Every day we move a step closer to this goal by creating sustainable advanced technologies and products, using responsible marketing, and embracing a greener future.”
For more information or journalist queries, please contact us via feelm@smooretech.com.
About FEELM:
As a flagship tech brand belonging to SMOORE, FEELM is the world’s leading closed vape system solution provider. Based on the world's leading Ceramic Coil Heating Technology, FEELM combines authentic Flavor Reproduction Technology with innovative electronics technology, bringing ultimate sensation and premium vaping experience.
About SMOORE:
SMOORE is a global leader in offering vaping technology solutions, including manufacturing vaping devices, and vaping components for HNB products on an ODM basis, with advanced R&D technology, strong manufacturing capacity, wide-spectrum product portfolio and diverse customer base.
According to Frost & Sullivan, SMOORE is the world’s largest vaping device manufacturer in terms of revenue, accounting for 22.8% of the total global market share in 2021. Its global market share is bigger than the sum of those listed from No.2 to No.5.
About the UKVIA:
The UK Vaping Industry Association (UKVIA) is the #1 trade association for the vaping sector supporting, developing, and promoting the £1bn vaping industry, the UK’s largest growing consumer goods sector. Its vision is a world where the evidence-based, life-changing public health benefits of vaping products are fully understood so that their positive impact can be maximised.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221121005487/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom